2022-08-20 高雄萬豪酒店 10F皇喜會議室 10D-1
| 時間 | 主題 | 講者 | 座長 | 摘要 | 簡報 |
|---|---|---|---|---|---|
14:10 ~ 14:20 |
PD04-1: Active surveillance in Taiwanese men with localized prostate cancer: Outcomes and predicting models |
查舫宇 |
楊啟瑞, 王賢祥 |
||
14:20 ~ 14:30 |
PD04-2: Overall survival with Darolutamide versus placebo in combination with androgen-deprivation therapy and Docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial |
馮思中 |
楊啟瑞, 王賢祥 |
||
14:30 ~ 14:40 |
PD04-3: The role of urine metabolomics in predicting clinically significant prostate cancer |
陳忠信 |
楊啟瑞, 王賢祥 |
||
14:40 ~ 14:50 |
PD04-4: Comparison of the clinical outcomes of chemotherapy and novel hormone agents in pre-chemotherapy and post-chemotherapy settings for treatment of metastatic castration-resistant prostate cancer |
吳芃諺 |
楊啟瑞, 王賢祥 |
||
14:50 ~ 15:00 |
PD04-5: Prostate health index density outperforms prostate health index in clinically significant prostate cancer detection |
蔣智宏 |
楊啟瑞, 王賢祥 |
||
15:00 ~ 15:10 |
PD04-6: 4-year experience in cmuh for learning curve of MRI/Ultrasound fusion-guided prostate biopsy |
李柏毅 |
楊啟瑞, 王賢祥 |